Given the difference in ERK hyperactivation in CRPC compared to primary prostate cancer tissue, we postulated that ERK1/2 activation in primary tumors correlates with risk for biochemical failure after radical prostatectomy. Here, MAPK3 is linked to prostate carcinoma.